BB Biotech AG

Equities

BION

CH0038389992

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:30:28 2024-06-26 EDT			5-day change	1st Jan Change
40.6 ^CHF	+0.12%		+4.91%	-5.03%

04-27	Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	CI
04-26	Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps	MT

BB Biotech AG Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015

January 24, 2016 at 04:31 am

BB Biotech AG reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2015. For the quarter, the company reported profit of CHF 511 million.

For the year, the company reported profit of CHF 653 million against CHF 1,470 million a year ago.

Latest news about BB Biotech AG

Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	04-27	CI
Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps	04-26	MT
BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
BB Biotech's Loss Narrows in FY23; Operating Income Down	02-16	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	02-14	CI
BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	02-13	CI
BB Biotech Trims FY23 Dividend as Net Loss Narrows	01-19	MT
BB Biotech Names Successor to Outgoing Chair	01-19	MT
BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-20	CI
Switzerland's BB Biotech Swings to Q3 Loss; Operating Income Shrinks	23-10-20	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-10-20	CI
BB Biotech Shares to be Suspended from Euronext Star Milan Pending Delisting	23-08-21	MT
BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
Switzerland's BB Biotech to Scrap Listing on Italian Bourse	23-07-21	MT
BB Biotech Logs Decline in H1 Loss, Operating Income	23-07-21	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-07-21	CI
BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Europeans contrasted; gold below USD2,000 threshold	23-04-21	AN
Europeans without momentum ahead of PMIs	23-04-21	AN
BB Biotech Posts Lower Q1 Loss; Operating Income Falls	23-04-21	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-04-21	CI
Europeans down; auto sector suffers	23-04-20	AN
BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Swiss Investor BB Biotech's Loss Shrinks in FY22	23-02-17	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-02-17	CI

Chart BB Biotech AG

Duration

Period

More charts

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Sector

Biotechnology & Medical Research

Calendar

2024-07-26 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for BB Biotech AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.6 CHF

Average target price

47.7 CHF

Spread / Average Target

+17.49%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BB BIOTECH AG	-5.03%	2.48B
MODERNA, INC.	+23.13%	46.93B
LONZA GROUP AG	+37.49%	39.08B
IQVIA HOLDINGS INC.	-8.73%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	31.01B
CELLTRION, INC.	-12.26%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.57%	25.88B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+32.23%	12.53B
BIO-TECHNE CORPORATION	-6.56%	11.36B

Other Biotechnology & Medical Research